-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Results: The proportion of patients who took IXE and ADA reached ACR50 and PASI100 (39% vs 26%, p<0.
Results: The proportion of patients who took IXE and ADA reached ACR50 and PASI100 (39% vs 26%, p<0.
Conclusion: Compared with Ada to Wk52 , IXe is more effective in improving joints and skin of PSA patients
Literature source:
Smolen JS, Mease P, Tahir H, Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52, Ann Rheum Dis 2020 10;79(10)
Smolen JS, Mease P, Tahir H, Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52, Ann Rheum Dis 2020 10;79(10)Leave a message here